Compare RCAT & COLL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | RCAT | COLL |
|---|---|---|
| Founded | 2002 | 2002 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Wholesale Distributors | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.1B | 1.2B |
| IPO Year | 2017 | 2015 |
| Metric | RCAT | COLL |
|---|---|---|
| Price | $8.24 | $35.58 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 2 | 5 |
| Target Price | $20.00 | ★ $51.40 |
| AVG Volume (30 Days) | ★ 7.0M | 337.0K |
| Earning Date | 05-07-2026 | 05-07-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | N/A | ★ 0.40 |
| Revenue | $17,836,382.00 | ★ $780,567,000.00 |
| Revenue This Year | $271.60 | $8.01 |
| Revenue Next Year | $41.21 | N/A |
| P/E Ratio | ★ N/A | $88.48 |
| Revenue Growth | ★ 79.95 | 23.62 |
| 52 Week Low | $5.77 | $29.70 |
| 52 Week High | $18.78 | $50.79 |
| Indicator | RCAT | COLL |
|---|---|---|
| Relative Strength Index (RSI) | 44.72 | 46.95 |
| Support Level | $7.31 | $33.93 |
| Resistance Level | $8.85 | $35.76 |
| Average True Range (ATR) | 0.58 | 1.40 |
| MACD | 0.07 | -0.10 |
| Stochastic Oscillator | 54.78 | 28.38 |
Red Cat Holdings Inc is a drone technology company integrating robotic hardware and software for military, government, and commercial operations. Its suite of solutions includes the Arachnid family of ISR and precision strike drones, which includes the Black Widow, a small unmanned ISR system; and WEB (Warfighter Electronic Bridge) GCS, designed to command and control an entire drone family of systems for military operations. Its other offerings include Edge 130 Blue drone systems, Trichon, a fixed-wing VTOL for extended endurance and range, and FANG FPV drones optimized for military operations with precision strike capabilities. The firm's Division includes Teal, FlightWave, and Blue Ops.
Collegium Pharmaceutical Inc is a diversified biopharmaceutical company committed to improving the lives of people living with serious medical conditions. The company has developed, licensed, and acquired a portfolio of meaningfully differentiated products for the treatment of attention deficit hyperactivity disorder (ADHD) and moderate to severe pain. It commercializes its products in the United States, including Jornay PM, Belbuca, Xtampza ER, Nucynta ER, Nucynta IR (collectively, the Nucynta Products), and Symproic. The company's product portfolio includes Jornay PM, Belbuca, Xtampza ER, Nucynta IR, Nucynta ER, and Symproic.